Австралія - англійська - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - esomeprazole magnesium, quantity: 44.528 mg (equivalent: esomeprazole, qty mg) - tablet, enteric coated - excipient ingredients: polysorbate 80; hypromellose phthalate; pregelatinised maize starch; macrogol 6000; light magnesium oxide; purified water; povidone; glyceryl monostearate; silicon dioxide; microcrystalline cellulose; crospovidone; macrogol 400; purified talc; iron oxide red; lactose monohydrate; methacrylic acid - ethyl acrylate copolymer (1:1); hyprolose; titanium dioxide; hypromellose; maize starch; sucrose - esomeprazole enteric-coated tablet indicated for:,1] gastro-oesophageal reflux disease (gord),- treatment of erosive reflux oesophagitis,- long-term management of patients with healed oesophagitis to prevent relapse,- symptomatic treatment of gastro-oesophageal reflux disease (gord),2] patients requiring nsaid therapy,- short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,- healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,- prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,3] prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole solution administered by intravenous infusion.,4] pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,- healing of duodenal ulcer associated with helicobacter pylori,- eradication of helicobacter pylori in patients with active or healed peptic ulcer

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - topiramate, quantity: 200 mg - tablet - excipient ingredients: pregelatinised maize starch; lactose monohydrate; sodium starch glycollate type a; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; polysorbate 80; iron oxide red; macrogol 400 - 1. epilepsy. rbx topiramate tablets are indicated in adults and children, 2 years and over:. - as monotherapy in patients with newly diagnosed epilepsy. - for conversion to monotherapy in patients with epilepsy. - as add-on therapy in partial onset seizures (with or without secondary generalised seizures), primary generalised tonic-clonic seizures or drop attacks associated with lennox-gastaut syndrome.. 2. migraine. rbx topiramate tablets are indicated for the prophylaxis of migraine headache in adults.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - topiramate, quantity: 50 mg - tablet - excipient ingredients: lactose monohydrate; magnesium stearate; pregelatinised maize starch; microcrystalline cellulose; sodium starch glycollate type a; titanium dioxide; hypromellose; polysorbate 80; iron oxide yellow; macrogol 400 - 1. epilepsy. rbx topiramate tablets are indicated in adults and children, 2 years and over:. - as monotherapy in patients with newly diagnosed epilepsy. - for conversion to monotherapy in patients with epilepsy. - as add-on therapy in partial onset seizures (with or without secondary generalised seizures), primary generalised tonic-clonic seizures or drop attacks associated with lennox-gastaut syndrome.. 2. migraine. rbx topiramate tablets are indicated for the prophylaxis of migraine headache in adults.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - topiramate, quantity: 100 mg - tablet - excipient ingredients: lactose monohydrate; microcrystalline cellulose; sodium starch glycollate type a; pregelatinised maize starch; magnesium stearate; titanium dioxide; hypromellose; polysorbate 80; iron oxide yellow; macrogol 400 - 1. epilepsy. rbx topiramate tablets are indicated in adults and children, 2 years and over:. - as monotherapy in patients with newly diagnosed epilepsy. - for conversion to monotherapy in patients with epilepsy. - as add-on therapy in partial onset seizures (with or without secondary generalised seizures), primary generalised tonic-clonic seizures or drop attacks associated with lennox-gastaut syndrome.. 2. migraine. rbx topiramate tablets are indicated for the prophylaxis of migraine headache in adults.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - topiramate, quantity: 25 mg - tablet - excipient ingredients: pregelatinised maize starch; sodium starch glycollate type a; magnesium stearate; microcrystalline cellulose; lactose monohydrate; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - 1. epilepsy. rbx topiramate tablets are indicated in adults and children, 2 years and over:. - as monotherapy in patients with newly diagnosed epilepsy. - for conversion to monotherapy in patients with epilepsy. - as add-on therapy in partial onset seizures (with or without secondary generalised seizures), primary generalised tonic-clonic seizures or drop attacks associated with lennox-gastaut syndrome.. 2. migraine. rbx topiramate tablets are indicated for the prophylaxis of migraine headache in adults.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - risperidone, quantity: 4 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; pregelatinised maize starch; lactose monohydrate; sodium lauryl sulfate; purified talc; magnesium stearate; titanium dioxide; hypromellose; propylene glycol; iron oxide red - ? risperidone tablets are indicated for the treatment of schizophrenia and related psychoses. ? risperidone tablets are indicated for the short-term treatment of acute mania associated with bipolar 1 disorder (see section 4.2 dose and method of administration ? bipolar mania)). ? risperidone tablets are also indicated for the treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type. (see section 4.2 dose and method of administration: behavioural disturbances in dementia) ? risperidone tablets are indicated in the treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with sub average intellectual functioning or mental retardation in whom destructive behaviours (eg. aggression, impulsivity and self-injurious behaviours) are prominent. (see section 5.1 pharmacodynamic properties ? clinical trials for maintenance data). ? risperidone tablets are indicated for the treatment of behavioural disorders associated with autism in children and adolescents (see section 5.1 pharmacodynamic properties ? clinical trials)

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - risperidone, quantity: 3 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; pregelatinised maize starch; lactose monohydrate; sodium lauryl sulfate; purified talc; magnesium stearate; titanium dioxide; hypromellose; propylene glycol; iron oxide yellow - ? risperidone tablets are indicated for the treatment of schizophrenia and related psychoses. ? risperidone tablets are indicated for the short-term treatment of acute mania associated with bipolar 1 disorder (see section 4.2 dose and method of administration ? bipolar mania)). ? risperidone tablets are also indicated for the treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type. (see section 4.2 dose and method of administration: behavioural disturbances in dementia) ? risperidone tablets are indicated in the treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with sub average intellectual functioning or mental retardation in whom destructive behaviours (eg. aggression, impulsivity and self-injurious behaviours) are prominent. (see section 5.1 pharmacodynamic properties ? clinical trials for maintenance data). ? risperidone tablets are indicated for the treatment of behavioural disorders associated with autism in children and adolescents (see section 5.1 pharmacodynamic properties ? clinical trials)

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - risperidone, quantity: 2 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; pregelatinised maize starch; lactose monohydrate; sodium lauryl sulfate; purified talc; magnesium stearate; titanium dioxide; hypromellose; propylene glycol; sunset yellow fcf aluminium lake - ? risperidone tablets are indicated for the treatment of schizophrenia and related psychoses. ? risperidone tablets are indicated for the short-term treatment of acute mania associated with bipolar 1 disorder (see section 4.2 dose and method of administration ? bipolar mania)). ? risperidone tablets are also indicated for the treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type. (see section 4.2 dose and method of administration: behavioural disturbances in dementia) ? risperidone tablets are indicated in the treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with sub average intellectual functioning or mental retardation in whom destructive behaviours (eg. aggression, impulsivity and self-injurious behaviours) are prominent. (see section 5.1 pharmacodynamic properties ? clinical trials for maintenance data). ? risperidone tablets are indicated for the treatment of behavioural disorders associated with autism in children and adolescents (see section 5.1 pharmacodynamic properties ? clinical trials)

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - risperidone, quantity: 1 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; pregelatinised maize starch; lactose monohydrate; sodium lauryl sulfate; purified talc; magnesium stearate; titanium dioxide; hypromellose; propylene glycol - ? risperidone tablets are indicated for the treatment of schizophrenia and related psychoses. ? risperidone tablets are indicated for the short-term treatment of acute mania associated with bipolar 1 disorder (see section 4.2 dose and method of administration ? bipolar mania)). ? risperidone tablets are also indicated for the treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type. (see section 4.2 dose and method of administration: behavioural disturbances in dementia) ? risperidone tablets are indicated in the treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with sub average intellectual functioning or mental retardation in whom destructive behaviours (eg. aggression, impulsivity and self-injurious behaviours) are prominent. (see section 5.1 pharmacodynamic properties ? clinical trials for maintenance data). ? risperidone tablets are indicated for the treatment of behavioural disorders associated with autism in children and adolescents (see section 5.1 pharmacodynamic properties ? clinical trials)

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - clopidogrel hydrogen sulfate, quantity: 97.875 mg (equivalent: clopidogrel, qty 75 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; hydrogenated castor oil; hyprolose; lactose monohydrate; microcrystalline cellulose; titanium dioxide; hypromellose; triacetin; iron oxide red - for prevention of vascular ischaemia associated with atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease. ,acute coronary syndrome: clopidogrel tablets is indicated in combination with aspirin for patients with: ,- unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). clopidogrel tablets is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularization (surgical or pci, with or without stent); ,- st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, clopidogrel has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.